![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
Preview |
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
693kB |
| Item Type: | Editorial |
|---|---|
| Title: | CEBPA mutations in AML: site matters |
| Creators Name: | Bullinger, L. |
| Abstract: | In this issue of Blood, based on a retrospective analysis of 4708 acute myeloid leukemia (AML) cases, Taube et al evaluate the impact of CCAAT/enhancer binding protein a (CEBPA) mutations and show that it is especially in-frame mutations affecting the basic leucine zipper region (bZIP) of CEPBA that confer a favorable outcome, irrespective of their occurrence as biallelic (CEBPAbi) or single mutation (CEBPAsm). Compared with transactivation domain (TAD) mutations, this study strongly supports a previously undefined role of CEBPA bZIP mutations, which is reflected in a distinct disease biology including younger age, higher white blood cell counts, the presence of GATA2 mutations, and high complete remission rates and long median event-free and overall survival. |
| Keywords: | Acute Myeloid Leukemia, CCAAT-Enhancer-Binding Proteins, Mutation |
| Source: | Blood |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Volume: | 139 |
| Number: | 1 |
| Page Range: | 6-7 |
| Date: | 6 January 2022 |
| Additional Information: | Copyright © 2022 by The American Society of Hematology |
| Official Publication: | https://doi.org/10.1182/blood.2021013557 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
